LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Trial Details

NCT ID

NCT06978088

Phase

PHASE2

Sponsor

Zulfa Omer

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• LP-168
• Obinutuzumab

Locations (sample)

• Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

• Diagnosis of CLL or SLL meeting criteria established in the 2018 iwCLL criteria and requiring treatment. Patients with variation in flow cytometry …
• a) Note: Variation in flow cytometry is defined as patients who have atypical immunophenotyping for CLL (CD5 negative, CD23 negative or surface exp…
• Meet the criteria for inclusion into at least one of the following 2 cohorts:
• Cohort 1: One or more prior therapies for CLL/SLL including BCL2 inhibitor (BCL2i), and/or chemotherapy and/or BTK inhibitor (BTKi).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.